Boron compound uptake augmentation to use for neutron capture therapy.

硼化合物吸收增强用于中子俘获疗法。

• 批准号: 17591245
• 负责人: YOSHIDA Fumiyo
• 金额: $ 1.09万
• 依托单位: University of Tsukuba
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17591245/
• 关键词: BNCT; BSH; BSO; in vivo

Boron neutron capture therapy (BNCT) is a targeted radiation therapy using a boron (B^<10>) compound and thermal neutrons. Sodium borocaptate (BSH) is widly used for BNCT of brain tumor. We reported that BSH uptake was enhanced in combination with butionine sulfoximine (BSO) in vitro (Cancer Lett. 215 (2004) 61-67). In this study, we investigated influence of BSO on BSH distribution in vivo. 9L glicosarcoma cells were subcutaneously inoculated to right legs of Fisher 344 rats. After 2 weeks, the rats were divided into 3 groups, BSO+ group, BSO-group and untreated group (control). The rats were sacrificed at 3 hours, 6hours or 12 hours after injection, and samples of brain, blood, subcutaneous tumor, muscle, skin, liver and kidney were obtained. The results of the blood boron concentration were 55.2±15.0 μg/mg at 3 hours after injection, 20.2±14. μg/mg at 6 hours, 10.8 ±20.6 μg/mg in BSO+ group. On the other hands, in BSH only group, they were 8.1 ± 6.2 μg/rag, 3.4 ± 0.5 μg/mg, 1.3 ± 0.2 μg/mg, respectively. The boron concentration included in each tissues were in proportion to blood boron concentration.Since in vivo boron level was maintained with high concentration by BSO combination, we performed BNCT for the subcutaneous tumor which we made to the rats legs. As the result, a tumor reduced BSO+ group significantly in comparison with BSO-group.In conclusion, the uptake of BSH was enhanced in combination with BSO in vivo as well as in vitro.

硼中子俘获疗法(BNCT)是一种使用硼化合物和热中子的靶向放射疗法。硼碳酸钠(BSH)广泛用于脑肿瘤的BNCT。我们报告了BSH的摄取在体外与丁胺亚磺胺(BSO)联合使用时被增强(癌症Lett。215(2004)61-67)。在本研究中，我们研究了BSO对BSH在体内分布的影响。将9L胶质肉瘤细胞接种于Fisher 344大鼠右腿皮下。2周后，将大鼠分为3组，BSO+组、BSO-组和未处理组(对照组)。分别于注射后3h、6h和12h处死大鼠，取脑、血、皮下肿瘤、肌肉、皮肤、肝脏和肾脏标本。血硼浓度注射后3h为55.2±15.0μg/mg，6h为2 0.2±14.μg/mg，BSO+组为10.8±2 0.6μg/mg。单纯补肾活血组分别为(8.1±6.2)μg/mg、(3.4±0.5)μg/mg、(1.3±0.2)μg/mg。各组织中的硼浓度与血液中的硼浓度成正比，由于BSO联合应用可维持体内较高的硼浓度，因此我们对大鼠腿部皮下肿瘤进行了BNCT治疗。结果表明，与BSO-GROUP相比，肿瘤对BSO+的摄取显著减少。结论：BSH在体内和体外的摄取均增强。

项目成果

Yoshida F(+5 authors) Combination of boron and gadolinium compounds for neutron capture therapy. An in vitro study.

Yoshida F（5位作者）硼和钆化合物的组合用于中子捕获疗法。

• 发表时间: 2005
• 期刊: J.Exp.Clin.Cancer Res. 24
• 作者: Matsumura A;Yamamoto T;Zhang T
• 通讯作者: Zhang T

Perfusion-weighted magnetic resonance imaging of the spinal cord in cervical spondylotic myelopathy.

脊髓型颈椎病脊髓的灌注加权磁共振成像。

• 发表时间: 2006
• 期刊: Neurol. Med. Chir. (Tokyo) 46・12
• 作者: Uemura K;Matsumura A;Isobe T (+4 authors)
• 通讯作者: Isobe T (+4 authors)

Combination of Boron and Gadolinium Compounds for Neutron Capture Therapy. An In Vitro Study.

用于中子捕获疗法的硼和钆化合物的组合。

• 发表时间: 2005
• 期刊: Clin.Cancer Res. 24
• 作者: Matsumura A;Zhang T;Nakai K;Endo K;Kumada H;Yamamoto T;Yoshida F;Sakurai F;Yamamoto K;Nose T
• 通讯作者: Nose T

Matsumura A Excision of juvenile pilocytic astrocytoma of the midbrain after radiotherapy.

Matsumura A 放疗后中脑幼年毛细胞星形细胞瘤的切除术。

• 发表时间: 2006
• 期刊: Pediatr.Neurosurg. 42
• 作者: Tsuboi K;Matsuda W;Nakamura K;Takano S
• 通讯作者: Takano S

Boron distribution in normal and impaired vascular tissue

正常和受损血管组织中的硼分布

• 发表时间: 2006
• 作者: Wataro Tsuruta;Tetsuya Yamamoto;Kei Nakai;Fumiyo Yoshida;Kiyoshi Endo;Takao Tsurubuchi;Akira Matsumura
• 通讯作者: Akira Matsumura